Skip to content

Response to Periodontal Therapy in a Chronic Kidney Disease Population

Response to Non Surgical Periodontal Therapy in a Chronic Kidney Disease Population Candidates to Kidney Transplant

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03525457
Enrollment
65
Registered
2018-05-15
Start date
2018-08-06
Completion date
2019-12-31
Last updated
2018-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease Stage 5, Periodontal Disease

Keywords

Glomerular filtration rate, Periodontitis, Chronic kidney disease

Brief summary

This study will evaluate periodontal and systemic parameters of a cohort of chronic kidney disease (stage 5) patients, before and three months after non-surgical periodontal treatment. It does not consider a control group.

Detailed description

Dental biofilm is a source of inflammation and infection of periodontal tissues. In the last 20 years the interaction between periodontal infections and systemic conditions has been largely studied, suggesting that the inflammation caused in the periodontal tissues could cause a response in other parts of the body. Recent studies suggest that there could be an association between periodontal disease and chronic kidney disease.

Interventions

PROCEDURENon Surgical Periodontal Therapy

Non Surgical Periodontal Therapy in 2 to 3 sessions

Sponsors

Pontificia Universidad Catolica de Chile
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Chronic kidney disease patients in Stage 5 (candidates to renal transplant)

Exclusion criteria

* Younger than 18 year old.

Design outcomes

Primary

MeasureTime frameDescription
Change in Clinical Attachment Level (CAL)3 monthsChange from baseline CAL (in mm) at three months

Secondary

MeasureTime frameDescription
Change in Bleeding on probing (BOP)3 monthsChange from baseline BOP (%) at three months

Countries

Chile

Contacts

Primary ContactMaite C Souyet, MsC
msouyet@gmail.com+56978786186
Backup ContactPatricio F Smith, PhD
psmithf@uc.cl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026